EcoSynthetix’s third-quarter results were mixed: sales fell sharply, but adjusted EBITDA was close to break-even, and the company added a new commercial account. Investors will want to know whether that account can help sales recover.
EcoSynthetix Inc. (TSX: ECO) reported results on November 3, 2026, for the quarter ended September 30. Calendar data lists EPS of -C$0.0062, but there’s no estimate for the quarter, so investors can’t use it to assess a beat or miss. The company’s release, as summarized in supplemental coverage, reported sales of US$3.6 million, down 38% from a year earlier, and adjusted EBITDA of US$39,400. It also announced a new commercial account with a global top-five tissue producer and reported US$29.4 million in cash and term deposits. For more company information, see the ECO stock page.
Recent earnings trend
EcoSynthetix Inc
ECO.TO
ECO.TO
EcoSynthetix Inc
WealthAwesomeMarket cap
$102.29M
52W high
$4.86
52W low
$1.26
1W change
+28.89%
Beta
0.58
Analyst Price Targets
Based on analyst covering ECO · as of Sep 17, 2026
Wall Street analysts forecast ECO stock price to rise 382.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$8.39
+382.2% Upside
Current Price
C$1.74
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ECO's historical volatility
30-Day Vol
87.9%
Annualized
90-Day Vol
69.1%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.46
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.64 | C$1.21 – C$2.22 |
| 60 trading days | C$1.54 | C$1.01 – C$2.37 |
| 90 trading days | C$1.46 | C$0.86 – C$2.46 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-03 | -0.0062 | — | — |
| 2026-06-30 | 2026-07-28 | -0.0101 | — | — |
| 2026-03-31 | 2026-05-07 | -0.0138 | — | — |
| 2025-12-31 | 2026-02-19 | 0.0036 | — | — |
| 2025-09-30 | 2025-11-06 | -0.0021 | — | — |
| 2025-06-30 | 2025-07-29 | 0.0026 | — | — |
Investor takeaway: Sales contracted sharply, while adjusted EBITDA stayed slightly positive and the company added a new customer account. That account is a foothold, not proof of a revenue recovery. Investors should watch for repeat orders and signs that sales are stabilizing. The calendar EPS figure shows a small loss, but without a quarter-specific estimate, it can’t be called a beat or miss. The recent-earnings trend table and chart provide historical context, not an estimate for this quarter.
Sales fell 38% year over year
EcoSynthetix reported Q3 sales of US$3.6 million, down 38% from a year earlier, according to the supplemental summary of its release. The decline is a bigger concern for the company’s momentum than its modestly positive adjusted EBITDA. The new account could matter over time, but the available information doesn’t say how much revenue it may bring in.
Bull case
The new account with a tissue producer could help EcoSynthetix expand its commercial reach if it leads to repeat business. Adjusted EBITDA of US$39,400 put the company close to break-even on that measure. Its US$29.4 million in cash and term deposits also represents a substantial reported liquidity position compared with its roughly C$102 million market capitalization. These figures offer some flexibility, but they don’t guarantee growth or future profits.
Bear case
The 38% drop in year-over-year sales is the clearest warning in the results. Adjusted EBITDA was positive but modest. The fundamentals snapshot also shows trailing-twelve-month EPS of -C$0.03 and a profit margin of -6.31%. The next test is whether the new account brings in enough business to offset weak sales. One customer win doesn’t show that a recovery is underway.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
